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An accurate identification of different species of Mycobacterium provides to allow 
appropriate treatment for Mycobacterium tuberculosis infection. Beside that, drug 
resistance of M. tuberculosis strains to rifampin is not clearly understood in 
contributing to the spread of tuberculosis in Indonesia. To assess the molecular 
mechanism of rifampin resistance, a number of clinical specimens of                              
M. tuberculosis were analyzed their molecular nature of a part of the rpoB gene 
using polymerase chain reaction-single strand conformation polymorphism               
(PCR-SSCP) methods. DNA’s extracted from sputum samples were amplified and 
32P-labeled by PCR with the specific primers and the product was analyzed their 
mutation conferring resistance by MDE gel electrophoresis. Of the 70 specimens 
tested, 57 specimens were positive for M. tuberculosis organism only, three 
specimens contained a mixture of M. tuberculosis and non tuberculosis 
mycobacteria (NTM), and 10 specimens were negative approved by Duplex PCR. 
Of these sixty DNA positive samples (thus the sensitivity of PCR was 85.71%),               
5 (8.3%) of them suspected to contain mutations in rpoB which were associated 
with rifampin resistance. Even though the frequency of mutation was low, the 
results from our study clearly indicate that the molecular mechanism of rifampin 
resistance in M. tuberculosis isolates from Indonesia involves alterations in the     
rpoB gene. Molecular diagnosis by PCR which is fast and easy to perform is useful 
for early and rapid detection of TB in sputum specimen. 
 
© 2010 Atom Indonesia. All rights reserved 
 
 
INTRODUCTION 
 
Tuberculosis (TB) is the leading cause of 
mortality in adults due to an infectious agent called 
M. tuberculosis and accounts for 26 % of all 
preventable adult deaths globally [1]. TB has also 
emerged as a major public health problem in 
Indonesia. Therefore, it should be the first priority 
disease requiring proper treatment and research 
efforts. The prevalence of TB was 0.29% (0.24% on 
the basis of positive sputum smears), and 5.6% of 
the world’s 7.5 million new cases of TB in 1990 
[2,3]. With nearly 557,000 TB cases where 175,000 
deaths annually and an incidence rate of 115 new 
sputum smear positive cases per 100,000 population 
by 2002, TB ranks second among the leading causes
 
of death in this country [4] and the first rank among 
the communicable and infectious diseases. 
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Therefore, a rapid detection and treatment of cases is 
urgently needed and currently the key strategy to 
control the spread of TB. However, the effectiveness 
of this control strategy is being limited because of 
the emergence and spread of drug-resistant TB, 
particularly multidrug-resistance tuberculosis 
(MDR-TB) which indicating the resistance to at least 
isoniazid and rifampin [5]. This resistance results 
from inadequate treatment, but often because of an 
irregular drug supply, inappropriate regimens, or 
poor compliance. Although there is also growing 
concern about the increasing incidence of MDR-TB 
which is considered a major threat in developing 
countries, its prevalence in Indonesia was noted to 
be as low as 0.7% according to World Health 
Organization (WHO) Mission Report 2004               
(PPM DOTS in Indonesia: A Strategy for action). 
Species
 
identification of Mycobacterium can 
be achieved by biochemical and conventional tests 
but it has proven to be difficult to use these tests
 
because of time-consuming and often incorrect 
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identification [6].
 
In order to overcome such 
difficulties, several molecular tests supported by the 
availability
 
of genome sequencing data have been
 
developed and many genes are the targets for 
molecular technique-based
 
species identification 
such as Duplex PCR [7]. Substantial progress has 
been made in understanding of the molecular basis 
of M. tuberculosis drug resistance in the last two 
decade [8]. Understanding the genetic events that 
lead to drug resistance in clinical M. tuberculosis 
isolates is important for the development of genetic 
assays, elucidation of the mechanisms of action of 
antimicrobial agents, and the design of novel 
antibiotics that are active against drug-resistant 
strains [9]. Drug resistant strains emerge when 
chemotherapy is intermittent or otherwise 
inadequate. Several factors influence the degree of 
success of treatment programs including duration 
and complexity of therapy, ease of healthcare access, 
treatment cost, patient adherence, and drug side 
effects [10]. 
Rifampin is an approved anti-mycobacterial 
drug that is a standard component of combination 
regimens and first line medication for treating TB. 
The highly effective bactericidal action of this drug 
against M. tuberculosis has made it a key component 
of the initial anti-tuberculous regimen. Analysis of 
approximately 500 rifampin strains from global 
sources has found that 96% of rifampin resistant 
clinical isolates of M. tuberculosis have mutations in 
the 81-bp core region of rpoB, a kind of house-
keeping gene, which encodes the beta-subunit of 
RNA polymerase [8,11] and apparently blocks the 
entry of the first nucleotide which is necessary to 
activate the polymerase, thereby blocking mRNA 
synthesis. Mostly missense mutations caused 
rifampin resistance were found in codons 513, 526, 
or 531 of rpoB, whereas amino acid changes at 
position 514 or 533 usually result in low levels of 
rifampin resistance [8]. It is estimated that 90% of 
rifampin-resistant isolates in some areas are also 
resistant to isoniazid, making rifampin resistance a 
useful surrogate marker for multidrug resistance and 
indicating that second and third line drugs to which 
these isolates are susceptible are urgently required 
[12,13]. It has been found to have greater 
bactericidal effect against M. tuberculosis than other 
anti-tuberculosis drugs, and it has largely replaced 
isoniazid as one of the front-line drugs used to treat 
the disease, especially when isoniazid resistance              
is indicated.  
Delineation of the molecular mechanisms of 
antimicrobial agent resistance has resulted in the 
development and application of several Polymerase 
Chain Reaction (PCR)-based strategies designed to 
rapidly detect mutations associated with resistance 
[14] such as duplex [15], multiplex [16,17], real time 
[18,19] or nested PCR [20,21] and PCR-enzyme 
linked immunosorbent assay (ELISA) [22]. Genomic 
detection by PCR has been reported to be a rapid, 
simple,
 
and very sensitive tool for detecting 
mycobacteria in clinical
 
samples. This paper 
represents the results of molecular identification and 
analysis for the detection of drug resistance in 
sputum DNA isolated from TB patient in Jakarta and 
is theoretically able to provide a same-day diagnosis 
from clinical samples.  
 
 
EXPERIMENTAL METHODS 
 
Clinical Samples 
 
Seventy sputum specimens were obtained in 
2003-2005 from individuals (55 women and              
15 men; mean
 
age ± standard deviation, 67 years ± 
15.2 years) who were out patients in Health              
Center for Lung Diseases or Indonesian 
Tuberculosis Eradication Association (Perkumpulan 
Pemberantasan Tuberkulosis Indonesia, PPTI), a 
non-governmental organization, located at Jl. Sultan 
Iskandar Muda 66A in South Jakarta (50 samples) 
and Lung Disease Health Center (Balai Pengobatan 
Penyakit Paru-paru, BP4) located at Jl. Prof. dr. 
Suharso 28 Surakarta Central Java (20 samples). 
These patients were suspected of having 
tuberculosis, with positive response to acid fast 
bacilli (AFB) by Ziehl-Neelsen staining. Two to five 
milliliters of expectorated early-morning sputa was 
transferred in sterile cups to the laboratory, where a 
direct
 
smear was prepared.  If any of the samples 
contained >3 bacilli it was categorized as AFB 
positive. For decontamination and homogenization, 
sputum samples were added with equal volume of 
4% NaOH and disrupt the cell wall by rotary 
shaking at speed 500 for 20 min. After washing with 
saline twice, pellet was used for DNA extraction. 
 
 
Extraction of Mycobacterial DNA from 
Sputum Samples 
 
DNA isolation from clinical specimens was 
performed as previously described [7]. Five hundred 
microlitter of sputum specimens were digested and 
decontaminated with the same volume of N-acetyl 
L-cysteine NaOH-Na citrate (NALC) solution. One 
part of NALC pellets was inoculated onto 
Löwenstein-Jensen
 
slants and incubated for up to            
6-8 weeks
 
at 37°C and other part was for extraction 
of DNA. All procedures to inoculate and extract 
DNA were performed in a biological safety cabinet. 
Decontaminated specimen was transferred to a 
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sterile microcentrifuge
 
tube and shaked in rotary 
shaker for 20 min. Samples were
 
then centrifuged, 
and the pellet was washed twice with sterile distilled
 
water. After recentrifugation the pellet was 
resuspended in 500
 
µl of deinozed water containing 
5 µl of proteinase-K (0.25 mg/ml) and incubated
 
at 
56°C for 1 h followed by boiling for 10 min. 
Samples were then
 
centrifuged, and the supernatant 
was used for PCR
 
amplification. In order to check 
for possible contamination, a negative control 
consisting of all the reagents except target DNA was 
run
 
in parallel with the samples in every set of 
amplification
 
reactions.  
 
 
Duplex PCR 
 
The Duplex PCR for differentiation of 
M. tuberculosis and MOTT was done with primer 
sets of rpoB constructed from the specific 
nucleotides of the M. tuberculosis or NTM strains 
located at the 3′-hydroxyl end of each primer, as 
previously reported [7, 15]. The developed Tbc1  
(5′-CGT ACG GTC GGC GAG CTG ATC CAA-
3′)-TbcR5 (5′-C CAC CAG TCG GCG CTT GTG 
GGT CAA-3′) and M5 (5′-G GAG CGG ATG ACC 
ACC CAG GAC GTC-3′)-RM3 (5′-CAG CGG GTT 
GTT CTG GTC CAT GAA C-3′) primer sets 
amplify a 235-bp DNA sequence from the                      
M. tuberculosis complex and a 136-bp DNA 
sequence from NTM, respectively. Primers (10 pmol 
of Tbc1-TbR5 and 20 pmol of M5-RM3) and 3 μl of 
bacterial DNA were added to a PCR mixture tube 
(AccuPower PCR PreMix; Bioneer, Daejeon, Korea) 
containing 2 U of Taq polymerase, 250 μM each 
deoxynucleoside triphosphate, 10 mM Tris-HCl        
(pH 8.3), and 1.5 mM MgCl2, and water was added 
to a final volume of 20 μl per reaction mixture. PCR 
was performed with an initial denaturation of 95°C 
for 5 min, 30 cycles of amplification (30 s at 95°C,     
30 s at 74°C, 4 min at 74°C), and a final elongation 
at 74°C for 5 min (BioRad Gene Cycler, Japan). The 
PCR products were analyzed by agarose gel (1.5%) 
electrophoresis.  
 
 
Detection of Amplified Products 
 
Amplified products were resolved 
electrophoretically on 1.5% agarose (Sigma Aldrich, 
Inc.) made up in 1.0X TAE  (Tris-Acetate-EDTA) 
containing ethidium bromide (0.5 µg/ml) and 
visualised on 260 nm wavelength UV 
transilluminator (Chromato-Vue San Gabriel CA, 
Model TM36) completed with Foto/Analyst Mini 
Visionary Fotodyne Inc., Model No. 69 and 
Mitsubishi Video copy processor P67UA.  
Nested PCR 
 
One tube nested PCR was done with TB1              
(5'-ACG TGG AGG CGA TCA CAC CGC AGA 
CGT-3')
 
and TB2 (5'-TGC ACG TCG CGG ACC 
TCC AGC CCG GCA-3') as outer primers and TB3                
(5'-TCG CCG CGA TCA AGG AGT TCT TC-3') 
and TR8 (TGC ACG TCG CGG ACC TCC-3’) as 
inner primers as described in previous report [7, 23]. 
PCR was performed
 
in a tube (AccuPower PCR 
PreMix; Bioneer) containing
 
2 U of Taq polymerase, 
10 mM Tris-HCl (pH 8.3), and 1.5 mM MgCl2,
 
and 
20 pmol of each TB1 and TB2 primers and 1.5 pmol 
of each TB3 and TB8 primers and then the volume 
was adjusted
 
to 20 µl. One microlitter (0.1 µCi) of    
[-32P]dCTP (Amersham International) was added 
to the reaction
 
mixture and was subjected to 
preheating at 94°C for 5 minutes and then followed 
by 15 cycles of first round amplification
 
(30 s at 
94°C, 1 min at 82°C) followed by the second 
amplification which was performed in 30 cycles
 
(30 s at 94°C, 1 min at 72°C) followed by a 5-min 
extension at
 
72°C in a BioRad Thermalcycler. The 
Rif
r
 reference strain (H37Rv ATCC 35838) that had 
a mutation in codon 531
 
(C T) was used as 
positive control. 
 
 
Single-strand Conformation Polymorphism 
(SSCP) 
 
SSCP technique was used to localize the 
mutation. Six microlitter of the radioactively
 
labelled 
nested PCR product was mixed with 6 µl of SSCP 
loading dye (95% formamide (Biorad), 0.5M EDTA 
and 0.05% Bromophenol blue (Biorad) denaturants). 
The samples were denatured at 95°C for 4 minutes 
and snap cooled
 
on ice and loaded on the 0.5X 
Mutation Detection Enhancement (MDE) gel (BMA, 
Rockland, ME, USA). Electrophoresis was run at 
constant watt at room temperature (in an air 
conditioned room at 20–25°C) for 6-7 hours. The 
MDE gels were transferred to
 
Whatman filter paper 
and covered with saran wrap. They were then dried
 
in a gel drier (Rapid Dry, Atto, Japan) for 0.45-1 
hour, exposed to x ray film
 
(AGFA) in a x-ray 
cassette at -80°C for 24-72 hours, and developed 
with Fuji Medical Processor 1200 Japan [24]. 
 
 
RESULTS AND DISCUSSION 
 
For identification of M. tuberculosis, a novel 
duplex PCR method that can amplify the 235- and 
136-bp rpoB DNAs of M. tuberculosis and NTM, 
respectively, with two different sets of primers was 
used to differentially identify 70 clinical isolates of 
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mycobacteria from tuberculosis patients from 
Jakarta and Surakarta areas of Indonesia in a single-
step assay. Showing 100% sensitivity and 
specificity, the duplex PCR method could clearly 
differentiate M. tuberculosis complex and NTM 
strains in term of size. Of the 70 specimens 
suspected containing M. tuberculosis, 57 specimens 
were positive for M. tuberculosis organism by 
duplex PCR and 10 others were negative. Three 
specimens contained a mixture of M. tuberculosis 
dan NTM approved by two bands seen in agarose 
gel (Fig. 1). Therefore, these patients should be 
treated with different regimen and may need a 
special condition of culture for subsequent studies. 
Fig. 1 shows the results of electrophoresis of 8 PCR-
amplified samples. Of the 8 amplified products, 5 
showed the electrophoretic pattern of 1 DNA band 
of 235 bp, which corresponded to M. tuberculosis. 
The amplified size of 3 samples were 136 bp for 
NTM. The 3 other amplified products showed an 
electrophoretic pattern of 2 bands of 235 bp for                
M. tuberculosis and 136 bp for NTM. The negative 
controls consistently failed to yield detectable PCR 
products, whereas the positive controls always gave 
the expected PCR products.  
 
 
 
Fig. 1. Results of identification of M .tuberculosis with Duplex 
PCR that showing mixture of M. tuberculosis and NTM in 
samples no. 28 and 30. No any species was detected in samples 
no. 24, 25 and 26. M, PC and NC represent marker 100 bp, 
positive control and negative control, respectively. 
 
Analysis of rpoB mutation with SSCP 
technique identified the alteration of mobility shift 
of DNA band in acrylamide gel conferring mutations 
in the 81-bp core region of the rpoB gene in five 
(8.33%) clinical isolates of M. tuberculosis complex 
included in the
 
study. The results of SSCP-
autoradiography analysis were presented in Fig. 2 
that showing all five samples with pattern of DNA 
mobility shift similar with resistant reference strain 
(R) and different with susceptible strain (S). 
Genotypic evidence of rifampin resistance in 60 of 
70 AFB-confirmed, rifampin-resistant isolates was 
obtained by PCR, yielding specificity for the assay 
of 85.71%. These results demonstrate the feasibility 
of using a PCR-based assay directly on sputum 
specimens for simultaneous detection of                          
M. tuberculosis and rifampin resistance, and they 
suggest that patients with smear-positive, untreated 
tuberculosis and those presenting with suspected 
drug-resistant tuberculosis are the most appropriate 
groups for testing by PCR. 
 
Fig. 2. Results of electrophoresis with MDE gel for SSCP 
analysis of the rpoB gene. The resistance to the RIF was seen in 
samples no. 28, 42, 63, 64 and 67. S is standard sample for 
susceptible strain and R is resistant strain. Electrophoresis was 
done for 8 hours in room temperature and 40.5 hours exposure 
of autoradiography. 
 
Despite a highly effective chemotherapy, 
tuberculosis currently kills more people than any 
other infectious disease and is still a leading killer of 
young adults worldwide mainly in developing 
countries. Resurgence of tuberculosis in the early 
1990s has successfully been controlled and largely 
reduced in Indonesia by implementing the DOTS 
strategy adopted from WHO by National Movement 
Program on TB (Gerdunas TB) where 98% of the 
country’s population had been covered by year 2001 
[25]. However, the risk of contracting this disease is 
being resurgent when economical crisis was weaving 
in 1998. With the increase in drug-resistant                   
M. tuberculosis strains, the need for an improved 
genetic elucidation has become an international 
priority [10]. In Indonesia, however, the frequency 
of the mutations that conferring the resistance of 
Mycobacterium to the TB drugs has not been fully 
investigated, moreover with nuclear technique of 
which it was proven to be 8-10 times more sensitive 
compared to Giemsa or Silver staining. Furthermore, 
not many studies have used sputum specimens to 
detect these point mutations due to limited facility 
and fund. Beside that, the results obtained in our 
study must be validated with a great number of 
RMP-resistant strains for different region in 
Indonesia. Unfortunately, it
 
was not possible to draw 
any conclusions for RMP because
 
of the low number 
of sample analyzed compared to the extremely high 
burden of TB patients. 
Although rifampin is a key drug in 
tuberculosis treatment, its molecular mechanism 
causing resistance is little known in countries 
endemic for tuberculosis such as Indonesia. 
Therefore, a rapid and accurate diagnosis and 
effective treatment of tuberculosis are cornerstones 
in the prevention of this worldwide
 
epidemic. Nested 
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PCR is one of such tools. Gene amplification 
techniques for the diagnosis of M.
 
tuberculosis in 
respiratory specimens like sputum, along with 
traditional
 
smear and culture methods, despite their 
limitations, have attracted considerable interest in 
developing countries with all problems behind [18]. 
Because of the widespread use, it has caused the 
rifampin-resistant strains, threatening its usefulness 
in treating mycobacterial diseases. Previous 
technique for monitoring of suspected cases of 
rifampin resistance was the extremely long 
susceptibility test. Improvements are needed to yield 
accurate analysis in the shorter time and for small 
bacillary number materials. DNA diagnostic assays 
have the potential to provide rapid analysis of 
rifampin resistance in mycobacteria because of their 
high degree of sensitivity and specificity and the fact 
that they do not rely on in vitro growth for results. 
Shortening the time between diagnosis and the onset 
of effective therapy should decrease the number of 
patients. Therefore, rapid and sensitive detection of 
mutations at the rpoB gene of M. tuberculosis would 
be of great importance for proper management of TB 
patients and control of multi-drug resistant TB. 
PCR-SSCP using both radioisotopic and non-
radioisotopic methods have been widely used for 
detecting such mutations [26,27]. Radioactive 
labeling techniques are of major importance in the 
study of DNA examinations in bacteria. The 
radioisotope-based PCR-SSCP with an 8 to 10-fold 
higher sensitivity over the color-based method such 
as silver staining would be of great advantage                 
in applying such technology directly to                   
clinical samples.  
In microbiology, DNA amplification using 
PCR has allowed great progress to be made in the 
rapid and accurate diagnosis of infections due to 
organisms that are not cultivable by in vitro means, 
that require complex media or cell cultures and 
prolonged incubation times, or for which culture is 
too insensitive. Amplification techniques for the 
diagnosis of tuberculosis have attracted considerable 
interest, particularly with the hope of shortening the 
time required to detect and identify M. tuberculosis 
in respiratory specimens [28]. However, despite 
numerous reports in the literature [29-32], 
amplification techniques do not yet have an 
established role in the laboratory for tuberculosis 
diagnosis, nor have they replaced traditional 
techniques, in contrast to diagnostic modalities for 
other pathogens, like Chlamydia or Mycoplasma 
[28]. PCR-based assays can provide rapid 
identification of pathogens by selective 
amplification of species- or strain-specific regions of 
the bacterial genome [33]. Isolating template DNA 
from sputum that is free of PCR inhibitors is an 
essential component of any PCR assay and the 
method should be rapid and simple to use but a 
reliable process for cell lysis is always required. 
Most other PCR-based methods detect only the 
presence
 
of a mutation, not the actual substitution in 
the rpoB gene.
 
This limits our ability to estimate the 
level of resistance
 
to rifampin and may lead to false-
positive and false-negative
 
reports. Nevertheless, 
there is a need to quantify antibiotic
 
resistance in 
order to manage and control MDR-TB.
 
 
We found a low frequency of resistance of 
Mycobacterium tuberculosis to rifampin. This is in 
accordance to other drug susceptibility testing that 
demonstrated a low rate of resistance to                   
drugs used for TB treatment in Indonesia.                
Low-frequency of genetic alterations
 
in rpoB gene 
region associated with in-vitro resistance to rifampin
 
and rifabutin was also found by others [34-36]. 
Moreover, the clinical implications and
 
the 
diagnostic utility of their detection remain 
controversial. Although several different molecular 
techniques such as heteroduplex analysis, line probe 
assay, and PCR-SSCP have been used for analysis of 
rpoB gene mutations, these techniques were limited 
in that only the most frequent types of mutations 
were included. In this research, the rpoB gene of 
clinical isolates of M. tuberculosis was amplified to 
assess the efficiency of PCR amplification from 
clinical isolates using radioisotopic nuclides, rather 
than non radioisotopic nuclides. It was known that 
the efficiency of PCR for amplifying the rpoB gene 
from clinical strains of M. tuberculosis was slightly 
higher than that of ethidium bromide staining              
(data not shown), indicating that radioisotopic 
nuclides did not interfere with amplification 
efficiency of PCR. Moreover, the major limiting 
factor of successful detection of mutation of the 
rpoB gene from clinical samples will be sensitivity 
of PCR-SSCP. Therefore, the radioisotope-based 
PCR-SSCP with an 2 to 3-fold, or even 8-10 times 
as results of Lee, H. et al. [26], higher sensitivity 
over the ethidium bromide staining method would be 
of great advantage in applying such technology 
directly to clinical samples. Our study did not find 
any higher sensitivity of radioactive labeled DNA 
compared to conventional ethidium bromide staining              
(data not shown).  
We have shown an association between 
mutations in a short segment of the rpoB gene and 
phenotypic rifampin resistance in five                         
M. tuberculosis isolates. It has been widely known 
that rifampin resistance in M. tuberculosis has been 
shown to be predominantly due to mutations in an 
81-bp region of the rpoB gene designated                      
the rifampin resistance-determining region. 
Interestingly, the substituted amino acids in our 
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rifampin-resistant strains reflected the most 
commonly found residues in clinical rifampin-
resistant M. tuberculosis isolates. In view of recent 
studies using rpoB gene sequencing to determine 
mycobacterial species [37], analysis of this gene has 
the potential to provide rapid information on both 
species and rifampin susceptibility of organisms 
such as M. kansasii and M. tuberculosis. A mutation 
in Hys526Tyr of rpoB gene was found in Indonesian 
sample analyzed by Hirano et al with reverse 
hybridization-based line probe assay (INNO-LiPA 
Rif TB) [38]. This kind of mutation in rpoB gene 
(Hys526Tyr) was also found in Indonesian samples 
(5 out of 30 samples) analyzed by Maeda et al. [39]. 
One mutation resulted in Asp516Asn was also found 
in these samples. 
We and others have shown that mutations in 
the RNA polymerase (rpoB) gene of                          
M. tuberculosis are associated with rifampin 
resistance. Several investigators have reported on the 
utility of the PCR-SSCP method for identifying 
mutations in genes of M. tuberculosis associated 
with resistance to rifampin with quite distinct results 
due to several factors [7,11-13,15,17,19,20]. For this 
method, mobility shifts in high-resolution 
nondenaturing polyacrylamide gels are discernible 
for single-stranded mutated DNA versus wild-type 
DNA. After amplification of the target nucleic acid 
by PCR, it is denatured to a single strand and then 
electrophoresed. Mutations are inferred by the 
appearance of bands at positions different to those 
observed with the wild-type strain (Fig. 2). We have 
determined that the size of the PCR product is a 
critical factor for resolving differences of the 
denatured single-stranded DNA. In our hands, the 
optimal PCR product is in the range of 310 to 320 
bp. A drawback of the conventional SSCP method 
has been the use of radioactivity for identifying 
amplification products as we did in this report. 
Screening for mutations prior to sequencing 
can reduce the time and costs of identifying 
mutations. When the DNA sequence is known, the 
technique of detecting mutations as SSCP is a 
convenient method of screening for possible 
mutations due to its technical simplicity and 
relatively high sensitivity for the detection of 
mutations. It has the ability of detecting a single base 
change, and has been applied to a big number of 
genes. It must be considered that detection and 
amplification of mutations in genes in a cheap and 
100% effective manner is a major objective in 
modern molecular genetics. SSCP is a reproducible, 
rapid and quite simple method for the detection of 
deletions, insertions, and rearrangements in PCR 
amplified DNA. SSCP identifies variation by 
distinguishing changes in the secondary structure of 
a single-stranded PCR product in response to 
changes in nucleotide sequence or single nucleotide 
polymorphism (SNP). It has been used successfully 
for detecting unknown mutations and for screening 
known mutations. The technique is simple and fits 
well in any laboratory where sequencing or 
genotyping is performed. SSCP has traditionally 
been performed on standard polyacrylamide gels, 
using P-32 isotope and autoradiography or ethidium 
bromide staining. SSCP is most useful for amplicons 
130 to 250 bp long. The optimal PCR fragment size 
for SSCP is 150 bp and that the percentage of 
mutations detected dropped with increasing 
fragment size and was compromised with very small 
fragments.
 
Sensitivity can vary among laboratories 
and loci, but published reports have shown it to be 
between 70% and 100% for fragments in this size 
range [40,41]. Some factors contributing to the 
sensitivity of mutation detection including choice of 
gel matrix, electrophoretic conditions, presence of 
neutral additives, fragment size, and G+C content.                    
A major advantage of SSCP is that many individual 
PCR products may be screen for variation 
simultaneously and much more efficient method              
of obtaining information about levels of 
polymorphisms within anonymous nuclear loci.  In 
this study, we used PCR and followed by SSCP 
where the abnormal band on a nondenaturing 
polyacrylamide gel was seen. MDE gel has 
advantages over conventional polyacrylamide in 
resolving subtle mobility difference in DNA. 
 
 
CONCLUSIONS 
 
In conclusion, of the 70 specimens tested, 57 
specimens were positive for M. tuberculosis 
organism only and three specimens contained a 
mixture of M. tuberculosis and non tuberculosis 
mycobacteria (NTM) approved by Duplex PCR. of 
these sixty DNA positive samples (thus the 
sensitivity of PCR was 85.71%), 5 (8.3%) of them 
suspected to contain mutations in rpoB which were 
associated with rifampin resistance. Even though 
low frequency, the results from our study clearly 
indicate that the molecular mechanism of rifampin 
resistance in M. tuberculosis isolates from Indonesia 
involves alterations in the rpoB gene. Molecular 
diagnosis by PCR which is fast and easy to perform 
is useful for early and rapid detection of TB in 
sputum specimen. It suggested that PCR analysis 
should be developed for relevant MDR-TB target 
genes in a large number of samples. Cumulative
 
data 
concerning the relationship between the phenotype, 
clinical
 
response, and type and position of mutations 
are recommended
 
to facilitate the rapid response 
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required to limit the extent
 
and severity of              
MDR-TB transmission and infection. It have been 
developed a highly sensitive and specific nested 
PCR capable of detecting M. tuberculosis
 
DNA in 
sputum specimens which is a most available sample 
taken from patients. 
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